Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and animal health. The global animal vaccine market is a valuable opportunity growing at an annual rate of 6% and is expected to reach US$13.4 billion by 2026.  Infectious diseases in animals cause significant economic loss to meat producers and also result in human infections. Increasingly, “zoonotic” diseases common to animals and humans are recognized as a part of the “One Health” concept, a worldwide strategy for expanding interdisciplinary collaborations in all aspects of health care for humans, animals and the environment. Pacific GeneTech’s technologies and business philosophy are fully aligned to One Health.

 

Founded in 2009, Pacific GeneTech was formed to globally commercialize a next-generation animal vaccine platform that was developed by a consortium of leading US universities, and partially funded by the US government. Our proprietary Aegis vaccine platform is the backbone for our first-in-class or best-in-class recombinant vaccines that provide broad protection against multiple strains and species of pathogens.  Pacific GeneTech has expanded beyond our first two poultry vaccines into pigs, ruminants (cows and sheep) and companion animals, and and we have an early stage human program in place for human bacterial dysentery (ETEC, Shigella, non-typhoidal Salmonella and Campylobacter) that causes over half a million deaths per annum, many of them children. Pacific GeneTech’s subsidiary, PGTx, is dedicated to developing this vaccine and has commenced programs with global collaborators.

 

Pacific GeneTech has developed research collaborations with other leading institutions around the world and continues to pursue other leading-edge vaccine technologies. 

​